WILMINGTON, DE — AstraZeneca has announced promising results from the BATURA Phase IIIb trial, showcasing the effectiveness of AIRSUPRA (albuterol/budesonide) in reducing the risk of severe asthma exacerbations. The trial demonstrated that when AIRSUPRA is used as a rescue medication, it significantly lowers the chance of severe asthma attacks compared to the traditional use of albuterol alone.
Conducted on patients with intermittent or mild persistent asthma, the trial assessed individuals on various existing treatments such as short-acting beta2-agonists (SABA), low-dose inhaled corticosteroids (ICS), or leukotriene receptor antagonists (LTRA). The findings underscore the potential of AIRSUPRA to address the needs of a large segment of asthma sufferers, as asthma affects over 25 million people in the US alone.
James Donohue, Emeritus Professor of Pulmonary Medicine and Chair of the Independent Data Monitoring Committee, commented on the results, stating, “People with asthma are at risk of severe exacerbations regardless of their disease severity or level of control. By focusing on patients with intermittent or mild persistent asthma, the strong BATURA trial results further demonstrate the clinically meaningful benefit of an anti-inflammatory rescue approach.”
Sharon Barr, Executive Vice-President of BioPharmaceuticals R&D at AstraZeneca, emphasized the trial’s impact on the treatment landscape, “The impressive BATURA trial results add to the body of evidence supporting AIRSUPRA as a first-in-class rescue treatment and its role in reducing the risk of asthma exacerbations in patients regardless of their disease severity.”
AIRSUPRA is notable for being the first anti-inflammatory rescue medication approved in the US for treating or preventing bronchoconstriction and reducing exacerbation risks in adults with asthma. Importantly, the safety profile of AIRSUPRA in the BATURA trial was consistent with previous findings, presenting no new safety concerns. AstraZeneca plans to present these findings at the upcoming American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting.
With its potential to transform asthma treatment, AIRSUPRA could provide a critical tool for patients and healthcare providers in managing asthma more effectively, offering a dual approach that tackles both symptoms and inflammation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.